Allurion Technologies offers the Allurion Smart Capsule, a swallowable, procedure-less gastric balloon designed to support weight loss without surgery. The capsule is marketed internationally alongside the Allurion Virtual Care Suite and other connected health devices that monitor patients throughout their program. In the United States, the Smart Capsule remains investigational; the company has now completed all four FDA PMA modules, passed both manufacturing and bioresearch inspections with zero findings, and finished its Day-100 Meeting without requests for additional human clinical data. To strengthen its balance sheet ahead of a potential U.S. launch, Allurion has arranged to exchange all outstanding Revenue Interest Financing debt for Series B Convertible Preferred Stock, which carries an 8.25% dividend and converts at $3.37 per share. Concurrently, the company raised $5 million through a private placement of common stock and warrants, bolstering working capital for commercialization efforts. When the debt exchange is finalized, the business will become debt-free, supporting its strategic focus on entering the U.S. market upon FDA approval. No revenue, user, or other operating metrics were disclosed in the article.

Total raised

$152M

Funding rounds

9

Latest round

Equity

Latest activity

Nov 2025